Showing results for "#Biocon"
Biocon gets USFDA nod for generic anti-cancer drug
The approval will further strengthen the company’s portflolio of vertically integrated, complex drug products, it added.
Biocon chief Kiran Shaw declared EY entrepreneur of 2019
London-headquartered professional services giant Ernst & Young (EY) honoured Biocon chief Kiran Mazumdar Shaw as the entrepreneur of the year 2019...
Biocon net down 42 pc quarterly, 17 pc yearly
Leading biotechnology firm Biocon reported Rs 123 crore consolidated net profit for the fourth quarter (Q4) of fiscal 2019-20, registering a 42 per...
Aim to list biosimilar arm within three years: Biocon
Biotechnology major Biocon aims to list its biosimilar unit in the next two-three years depending upon market conditions, as per the company’’s Annual...
Biocon’s Itolizumab drug gets approval for use on COVID-19 patients
Biocon has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe...
Biocon highlights details of its drug Itolizumab approved as...
Claiming that Itolizumab is a drug to save many lives, she said the DCGI gave permission for Biocon to market Itolizumab.
Biocon chief Kiran Mazumdar-Shaw tests Covid-19 positive
Biocon chairperson Kiran Mazumdar-Shaw on Monday night said she tested Covid-19 positive.
India to have Biocon Covid vaccine by June 2021, says Kiran...
Biocon on Friday submitted September quarter earnings, which saw a profit fall to Rs 169 crore from Rs 216 crore, mainly because of higher expenses by...
